1. Home
  2. TRDA vs ATGL Comparison

TRDA vs ATGL Comparison

Compare TRDA & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.29

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Technology Group Limited

ATGL

Alpha Technology Group Limited

HOLD

Current Price

$20.93

Market Cap

348.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
ATGL
Founded
2016
2017
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.8M
348.8M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
TRDA
ATGL
Price
$10.29
$20.93
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
167.3K
13.6K
Earning Date
11-06-2025
01-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$61,520,000.00
$1,206,460.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.36
52 Week Low
$4.93
$9.01
52 Week High
$18.76
$57.32

Technical Indicators

Market Signals
Indicator
TRDA
ATGL
Relative Strength Index (RSI) 53.45 44.28
Support Level $9.89 $19.81
Resistance Level $11.55 $21.19
Average True Range (ATR) 0.51 1.86
MACD -0.21 -0.60
Stochastic Oscillator 25.90 13.84

Price Performance

Historical Comparison
TRDA
ATGL

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About ATGL Alpha Technology Group Limited

Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.

Share on Social Networks: